Table 2 Pharmacokinetic parameters obtained alter the oral administration of 100:25 mg/kg levodopa/carbidopa in the three groups studied (initial situation; treatment with Plantago ovata husk and treatment with placebo) to 18 Parkinson patients

t _max (min)

35.83 ± 16.91

47.20

39.72 ± 17.19

43.28

36.17 ± 26.30

59.56

C _max (ng/ml)

603.2 ± 242.4

40.19

547.8 ± 192.6

35.16

612.0 ± 176.6

28.86

AUC (μg.min/ml)

62.87 ± 15.77

25.09

64.47 ± 15.27

23.69

65.10 ± 14.33

22.01

λ (min ^-1 )

0.0096 ± 0.0018

18.87

0.0088 ± 0.0020

22.54

0.0097 ± 0.0018

18.40

V _ss /F (l)

0.1845 ± 0.0628

34.05

0.1929 ± 0.0521

27.04

0.1699 ± 0.0468

27.58

Cl/F (l/min)

0.0017 ± 0.0004

25.98

0.0016 ± 0.0004

23.89

0.0016 ± 0.0004

22.52

AUMC (μg.min ² /ml)

7881.7 ± 2630.3

33.37

8313.7 ± 2284.4

27.48

8327.1 ± 2651.9

31.85

MRT (min)

125.1 ± 29.9

23.93

129.2 ± 21.7

16.78

126.6 ± 24.2

19.13

C _min (ng/ml)

6.02 ± 3.41

56.70

6.31 ± 7.10

112.58

7.34 ± 7.98

108.71

t _1/2λ (min)

75.2 ± 16.0

21.27

81.9 ± 15.3

18.70

74.0 ± 16.9

22.86